Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordThe US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- The US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
MISSION
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
POSITION SUMMARY
Reporting to the SVP of Corporate Development and Strategy, the Senior Director, New Product Planning will help shape the company’s future portfolio by leading commercial strategy for pipeline assets, identifying lifecycle opportunities, evaluating external innovation, and helping define new areas for growth.
This individual will serve as the commercial strategy lead for pre-Phase 3 programs and partner closely with Research, Clinical Development, Medical Affairs, US and International Commercial, Business Development, Corporate Strategy, and Finance to integrate scientific, clinical, commercial, and financial perspectives into key development and investment decisions.
The ideal candidate combines scientific depth with strong commercial judgment and strategic and financial acumen. A core aspect of the role is connecting science with strategy— to identify new indications, evaluate portfolio opportunities, and shape clinical development and investment decisions to align with unmet need, competitive landscape, and strategic value drivers.
JOB FUNCTIONS/RESPONSIBILITIES
Business Development & External Innovation
• Lead commercial assessments of licensing, acquisition, and partnership opportunities, integrating scientific rationale, unmet need, clinical profile, competitive landscape, commercial potential, pricing and market access, and strategic fit.
• Conduct primary and secondary market research to develop patient-based forecasts, scenario analyses, and risk-adjusted valuations to support investment and transaction decisions.
• Partner with Business Development, R&D, Finance, and US and Global Commercial throughout opportunity evaluation and diligence.
Pipeline & Lifecycle Strategy
• Serve as the commercial strategy lead on cross-functional product teams for pre-Phase 3 pipeline programs before transition
• Develop business cases and commercial strategies for pipeline assets, including indication prioritization, Target Product Profiles, patient segmentation, value story, competitive differentiation, market opportunity, and lifecycle planning.
• Partner with Research, Clinical Development, Market Access, and Medical Affairs to incorporate commercial considerations into development strategy, including patient populations, endpoints, comparators, and real-world / health economic evidence generation.
• Partner with US and Global Commercial leaders to incorporate perspectives from key markets and ensure effective transition of assets into late-stage commercial planning.
Portfolio & Corporate Strategy
• Evaluate new therapeutic areas and disease spaces by integrating disease biology, unmet need, competitive dynamics, development feasibility, and commercial potential.
• Shape portfolio and corporate strategy by identifying growth opportunities, strategic gaps, and priorities for investment and resource allocation.
• Own commercial assumptions that inform long range planning for all pre-Ph3 programs
• Monitor scientific, clinical, competitive, regulatory, and market developments and translate them into implications for product and portfolio strategy.
QUALIFICATIONS
Education /Experience:
• 10+ years of experience in the biotechnology or pharmaceutical industry, including significant experience in New Product Planning, Commercial Strategy, Portfolio Strategy, Business Development
Apply on employer site ↗